BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies

Opinion statement Melanoma is caused by a variety of somatic mutations, and among these mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a critical diagnostic biomarker in clinical practice. The introduction of targeted agents for BRAF-mutant melanoma has significa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current treatment options in oncology 2022-11, Vol.23 (11), p.1503-1521
Hauptverfasser:	Zhong, Jingqin, Yan, Wangjun, Wang, Chunmeng, Liu, Wanlin, Lin, Xinyi, Zou, Zijian, Sun, Wei, Chen, Yong
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Cancer therapies Clinical trials Drug Resistance, Neoplasm - genetics Humans Medicine Medicine & Public Health Melanoma Melanoma - etiology Melanoma - genetics Mutation Oncology Patients Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - genetics Section Editor Skin Cancer (T Ito Skin Cancer (T Ito, Section Editor) Topical Collection on Skin Cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!